# True North Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/true-north-therapeutics

- Industry: Pharmaceuticals
- Headquarters: South San Francisco, US
- Website: www.truenorthrx.com
- Total disclosed funding: $142M
- Latest round: Series D (Oct 6, 2016)
- Investors on record: 14

## About

True North Therapeutics, Inc. offers innovative healthcare solutions centered on pharmacy benefit management and pharmaceutical distribution, enhancing medication access while optimizing costs for healthcare providers and payers.True North Therapeutics, Inc. was founded in 2013 in South San Francisco, US, focusing on enhancing medication access. In May 2017, Bioverativ Inc. acquired the company for USD 400 mn, with an additional USD 425 mn dependent on future milestones. The company has completed a total of 7 deals, with the most recent deal occurring on May 23, 2017.True North Rx specializes in providing innovative healthcare solutions, focusing primarily on pharmacy benefit management services and pharmaceutical distribution. Their core offerings aim to streamline medication access for patients while optimizing costs for healthcare providers and payers. True North Rx serves a diverse client base, including health plans, employers, and healthcare providers, facilitating improved patient outcomes through effective medication management and adherence programs. The geographical markets for these products include the United States and Canada, targeting both urban and rural healthcare systems to maximize reach and impact.True North Rx generates revenue primarily through its pharmacy benefit management services, which operate on a B2B model, catering to health plans and employers. The company employs a transaction structure based on service agreements and subscriptions, allowing clients to access its services through tailored packages. Their offerings include tiered pricing plans based on the volume of medications managed and the specific services utilized, ensuring flexibility for different client needs. Flagship services encompass comprehensive medication management systems, which help reduce overall healthcare costs while enhancing patient care. Partnerships with various healthcare providers further facilitate seamless integration of their services into existing healthcare frameworks, fostering an efficient and cost-effective approach to medication management.Following the acquisition by Bioverativ Inc., True North Therapeutics is poised to leverage the resources for further growth. The company is set to enhance its product offerings and expand their reach in the pharmaceutical market. The funding from the acquisition will be used to support development and integration of new products into their existing service lines. True North aims to broaden its market presence across North America, targeting both urban and rural sectors by 2020. The most recent deal completed in May 2017 will allow True North to scale its operations effectively.

## Funding rounds

- Series D, Oct 6, 2016, $45M — Kleiner Perkins, OrbiMed Advisors, HBM Partners, New Leaf Venture Partners, MPM BioImpact, Redmile Group, Franklin Templeton, Cowen Investment Management, Perceptive Advisors, Baxalta Ventures
- Series C, Nov 24, 2015, $40M — Kleiner Perkins, OrbiMed Advisors, SR One, New Leaf Venture Partners, MPM BioImpact, Cowen Investment Management, Perceptive Advisors, Baxalta Ventures
- Series B, Apr 7, 2015, $35M — Kleiner Perkins, OrbiMed Advisors, SR One, MPM BioImpact, Baxter Ventures
- Series A, Jun 17, 2014, $8M — Kleiner Perkins, SR One, MPM BioImpact, Biogen Idec New Ventures, Baxter Ventures
- Series A, Nov 1, 2013, $10M — MPM BioImpact
- Series A, Aug 23, 2013, $3.7M — Kleiner Perkins, SR One, MPM BioImpact, iPierian, Inc., Biogen Idec New Ventures

## Investors

- Kleiner Perkins (https://capitalatlas.ai/funds/kleiner-perkins) — Series A, Series B, Series C, Series D
- SR One (https://capitalatlas.ai/funds/sr-one) — Series A, Series B, Series C
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series A, Series B, Series C, Series D
- iPierian, Inc. — Series A
- Biogen Idec New Ventures (https://capitalatlas.ai/funds/biogen-idec-new-ventures) — Series A
- Baxter Ventures (https://capitalatlas.ai/funds/baxter-ventures) — Series A, Series B
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series B, Series C, Series D
- New Leaf Venture Partners (https://capitalatlas.ai/funds/new-leaf-venture-partners) — Series C, Series D
- Cowen Investment Management — Series C, Series D
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series C, Series D
- Baxalta Ventures (https://capitalatlas.ai/funds/baxalta-ventures) — Series C, Series D
- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series D
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series D
- Franklin Templeton (https://capitalatlas.ai/funds/franklin-templeton) — Series D